INCY vs GMAB
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
INCY · Incyte$119.65 ▲ 1.39%
GMAB · Genmab$53.63 ▲ 1.69%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- INCY +12.9%
- GMAB +84.5%
Head to head
| Metric | INCY | GMAB |
|---|---|---|
| Price | $119.65 | $53.63 |
| Change today | ▲ 1.39% | ▲ 1.69% |
| Market cap | $24.39B | $33.47B |
| Return, 3 months | -1.6% | +73.7% |
| Return, year to date | +21.1% | +74.1% |
| Return, 1 year | +12.9% | +87.1% |
| P/E (TTM) | 61.0 | 45.8 |
| P/B | 4.3 | 5.3 |
| P/E percentile vs own 5y | 80th | 84th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +37.7% | +16.1% |
| Net profit growth (YoY) | +44.6% | -14.7% |
| Gross margin | 92.6% | 92.7% |
| Operating margin | 31.6% | 30.6% |
| Net margin | 27.7% | 17.0% |
| Return on equity | 30.7% | 12.1% |
| Analyst target vs. price | +14.3% | +20.7% |
| Analyst buy share | 56% | 89% |
| RSI (14) | 53 | 71 |
| 30-day volatility | 33.6% | 86.7% |
| Max drawdown, 1 year | -18.3% | -32.5% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GMAB is the largest of the group by market value.
- GMAB has returned the most over the past year.
- GMAB carries the lowest trailing P/E.
- INCY is growing revenue fastest.
- INCY keeps the most profit per dollar of sales.
- INCY has been the calmest stock over the last 30 days.